Abiopharma

DAYBU® (Trofinetide) vom CHMP für die Zulassung in der Europäischen Union empfohlen

Microsoft Corporation (MSFT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Nano-X Imaging Ltd. (NNOX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BitGo Holdings, Inc. (BTGO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Veritone, Inc. (VERI) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

FS KKR Capital Corp. (FSK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership

DAYBU® (trofinétide) recommandé dans l’UE par le CHMP pour le traitement du syndrome de Rett

SEGG Media Responds to False and Misleading Short Seller Report and Files $20 Million Lawsuit Against White Diamond Research and Adam Gefvert for Business Disparagement

DAYBU® (trofinetide) in de EU aanbevolen door CHMP voor de behandeling van het Rett-syndroom